Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

The BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, published by the ASSOC BRAS DIVULG CIENTIFICA, serves as a vital platform for the dissemination of cutting-edge research in the fields of medicine and biological sciences. With an ISSN of 0100-879X and E-ISSN 1414-431X, this Open Access journal has been championing free access to vital scientific knowledge since 1997. It is indexed in Scopus with notable rankings across various disciplines, including a rank of #131 in General Medicine (79th percentile) and #20 in Pharmacology, Toxicology, and Pharmaceutics (75th percentile). Covering a broad scope of topics, the journal primarily focuses on areas such as biochemistry, biophysics, immunology, neuroscience, and physiology, with a commendable categorization of Q2 and Q3 quartiles for several relevant fields in 2023. Through its commitment to high-quality research and robust peer review processes, the journal not only consolidates its reputation within the academic community but also significantly contributes to the enhancement of scientific knowledge and innovation in Brazil and beyond. Researchers, professionals, and students will find an invaluable resource in this journal, which is pivotal for those looking to stay abreast of the latest developments in medical and biological research.

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.

Biomedical Reports, published by SPANDIDOS PUBL LTD in Greece, is a distinguished open-access journal that focuses on the dynamic fields of biochemistry, genetics, molecular biology, medicine, pharmacology, and neuroscience. Established in 2014, the journal has rapidly gained recognition, securing Q2 and Q3 rankings in several categories for 2023, including a notable ranking of #125/636 in General Medicine, placing it in the 80th percentile amongst its peers. The journal continually aims to disseminate innovative research findings that advance the understanding of complex biomedical issues, making it an invaluable resource for researchers, professionals, and students alike. Its multidisciplinary approach not only reflects the interconnectivity of modern biomedical sciences but also promotes collaborative discourse among diverse fields, ensuring ongoing relevance and impact within the scientific community.